EASL Press Conference 2019 Upload video: No flash player has been set up. Please select a player to play Flash videos.
30May, 20MYR Pharmaceuticals receives positive CHMP opinion for HEPCLUDEX® (bulevirtide), the First-in-Class Entry Inhibitor for the treatment of chronic hepatitis D infectionsCommittee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive...
15Mar, 12Press Release, Moscow, March 15th, 2012Maxwell Biotech Venture Fund Invests in Hepatitis B/D Clinical Program Co-Invests with Germany’s Public/Private...
30Sep, 14Press Release, Moscow, October, 2014Maxwell Biotech Portfolio Company Hepatera Announces Proof-of-Concept Clinical Results with Myrcludex B, a Novel Entry...
23Oct, 18MYR Pharma Announces Grant of Breakthrough Therapy Designation by US FDA for Myrcludex, the First-in-Class Entry Inhibitor for Treatment of chronic Hepatitis B and D InfectionsMYR Pharma today announced that US Food and Drug Administration (FDA) has granted the Breakthrough Therapy designation...
